Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02774486
Recruitment Status : Completed
First Posted : May 17, 2016
Last Update Posted : January 3, 2018
Sponsor:
Information provided by (Responsible Party):
InQpharm Group

Brief Summary:

The primary cause of being overweight is an imbalance in calories consumed and energy expenditure. A surplus in energy intake might result in body fat deposition and thereby body weight gain. Therefore, food intake regulation is crucial to control the body weight gain.

Appetite regulation plays an important role in determining the food intake, which is a complex process influenced by the individual (physiology and psychology) and environment. Satiation (process that leads to the termination of eating) and satiety (decline in hunger, increase in fullness after a meal has finished) are the precursors of appetite regulation, which may be induced by various food components such as macronutrients, water, alcohol and non-digestible polysaccharides. High viscosity and swellable/bulking food components such as dietary fibre are expected to elicit stronger satiation/satiety than the macronutrients or clear liquid. Due to its unique physicochemical properties, dietary fibre has been recognized as potential ingredient that helps to enhance the sensation of satiety in the upper gut by increasing gastric distension and delaying gastric emptying, which subsequently reduces the food intake.

IQP-AK-102 comprises of a proprietary blend of dietary fibres known to promote a feeling a fullness. The objectives of this study are to evaluate the efficacy and safety of IQP-AK-102 on appetite reduction in overweight subjects during a 4-weeks interval.


Condition or disease Intervention/treatment Phase
Appetite Regulation Appetite Suppression Energy Intake Device: IQP-AK-102 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Clinical Investigation to Evaluate Efficacy and Safety of IQP-AK-102 on Appetite Reduction in Healthy Over- Weight Subjects
Actual Study Start Date : May 1, 2016
Actual Primary Completion Date : July 20, 2016
Actual Study Completion Date : July 20, 2016

Arm Intervention/treatment
Experimental: IQP-AK-102
2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
Device: IQP-AK-102
IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.




Primary Outcome Measures :
  1. Changes in appetite before and after breakfast 3 days a week (including one weekend day) using Haber Score (hunger, satiety) [ Time Frame: 6 weeks ]
    - Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake)

  2. Changes in appetite before and after breakfast 3 days a week (including one weekend day) using VAS (hunger, satiety, fullness, prospective food consumption). [ Time Frame: 6 weeks ]
    - Comparison between week 2 and week 3 (first week of the IP intake) as well as comparison between week 2 and week 6 (last week of the IP intake)


Secondary Outcome Measures :
  1. Changes in food intake using the subject diary [ Time Frame: 6 weeks ]
    Measured on the same days as appetite assessment (for breakfast, lunch, dinner, in between meal/snacks), during the run-in phase (three days a week, both weeks) and treatment phase (at first week of the IP intake (week 3),and during the last week of the IP intake, just before the V3, also three days a week).

  2. Changes in body weight using calibrated weighing scales (Tanita BC-420 SMA) [ Time Frame: 6 weeks ]
    Body weight (kg) is measured in subjects wearing underwear and no shoes

  3. Changes in BMI [ Time Frame: 6 weeks ]
    BMI is calculated as body weight (kg)/(height [m])2

  4. Changes in waist circumference [ Time Frame: 6 weeks ]
    Waist circumference (cm) is measured at the level midway between the lateral lower rib margin and the iliac crest

  5. Changes in hip circumference [ Time Frame: 6 weeks ]
    Hip circumference (cm) is measured as the maximal circumference over the buttocks

  6. Changes in body fat content using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA)) [ Time Frame: 6 weeks ]
    Measured as % and kg

  7. Changes in fat-free mass using validated electronic weighing scales according to the Body composition analyser BC-420MA (a bio-impedance analysis (BIA)) [ Time Frame: 6 weeks ]
    Measured as % and kg

  8. Global evaluation of efficacy by subjects [ Time Frame: 6 weeks ]
    The subjects will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor").

  9. Global evaluation of efficacy by investigator [ Time Frame: 6 weeks ]
    The investigators will evaluate independently the efficacy of the IP (globally scaled evaluation with "very good", "good", "moderate" and "poor").

  10. Blood pressure [ Time Frame: 6 weeks ]
    Measured using standard devices after an at least 5-minute rest

  11. Pulse rate [ Time Frame: 6 weeks ]
    Measured using standard devices after an at least 5-minute rest

  12. Global evaluation of safety by subjects [ Time Frame: 6 weeks ]
    The subjects will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor").

  13. Global evaluation of safety by investigator [ Time Frame: 6 weeks ]
    The investigators will evaluate independently the tolerability of the IP (global scaled evaluation with "very good", "good", "moderate" and "poor").



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and females, aged 18-65 years
  2. BMI ≥25 and BMI <30 kg/m2
  3. Generally in good health
  4. Regular daily consumption of 3 main meals (breakfast, lunch, dinner)
  5. Consistent regular physical activity (≤4 hours of strenuous sportive activity per week) AND willingness to maintain the same level of sport activity throughout the study
  6. Commitment to avoid the use of other weight loss and/or management products / programmes during the study
  7. Commitment to complete the subject diary correctly and to adhere to the lifestyle recommended for this study
  8. Stable concomitant medications (if any)
  9. Stable body weight for the last 3 months prior to V1 (less than 5% self-reported change)
  10. Subject's agreement to comply with study procedures
  11. Negative pregnancy testing (beta HCG-test in urine) at V1 in females of childbearing potential
  12. Women of child-bearing potential: willingness to use reliable method of contraception during the study period

Exclusion Criteria:

  1. Known sensitivity to the components of the investigational product
  2. Bariatric surgery in the last 12 months prior to V1
  3. Abdominal surgery within the last 6 months prior to V1
  4. Presence of any active gastrointestinal disease incl. stenosis in the gastrointestinal tract
  5. Malabsorption disorders
  6. Pancreatitis
  7. History of eating disorders like bulimia, anorexia nervosa, binge-eating (within the last 12 months prior to V1)
  8. Lack of appetite for any (unknown) reason
  9. Use of medications that could influence gastrointestinal functions such as antibiotics, laxatives, opioids, anticholinergics, anti-diarrheals 3 months prior to V1 and during the study
  10. Use of medications that could influence body weight (e.g. antidepressants) in the last 3 months prior to V1 and during the study
  11. Any medication or use of products for the treatment of obesity (e.g. fat binder, fat burner, satiety products etc.) or treatment that could influence food absorption, in last 3 months before V1 and during the study
  12. Gluten allergy
  13. History of abuse of drugs, alcohol or medication
  14. Exceeding moderate alcohol consumption (≥21 units /week; 1 unit is equal 1⁄2 l of beer, or 200 ml of wine, or 50 ml hard liquor)
  15. Smoking cessation within 6 months prior to V1 or during the study (regular smoking at the same level as prior to the study during the study is not an exclusion criteria)
  16. Inability to comply with study procedures (e.g. due to language difficulties etc.)
  17. Participation in similar studies or weight loss programs within the last 6 months prior to V1 and during the study
  18. Participation in other clinical studies within the last 30 days prior to V1 and during the study
  19. Clinically relevant deviations of laboratory values
  20. Any other reason deemed suitable for exclusion, per investigator's judgement

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02774486


Locations
Layout table for location information
Germany
Barbara Grube
Berlin, Germany, 10709
Sponsors and Collaborators
InQpharm Group
Investigators
Layout table for investigator information
Principal Investigator: Ralf Uebelhack, MD, PhD analyze & realize GmbH
Layout table for additonal information
Responsible Party: InQpharm Group
ClinicalTrials.gov Identifier: NCT02774486    
Other Study ID Numbers: INQ/025115
First Posted: May 17, 2016    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No